chr1-46196047-G-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_001290130.2(POMGNT1):c.-45C>T variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000136 in 1,613,836 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000014 ( 0 hom. )
Consequence
POMGNT1
NM_001290130.2 5_prime_UTR_premature_start_codon_gain
NM_001290130.2 5_prime_UTR_premature_start_codon_gain
Scores
11
5
3
Clinical Significance
Conservation
PhyloP100: 1.65
Genes affected
POMGNT1 (HGNC:19139): (protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-)) This gene encodes a type II transmembrane protein that resides in the Golgi apparatus. It participates in O-mannosyl glycosylation and is specific for alpha linked terminal mannose. Mutations in this gene may be associated with muscle-eye-brain disease and several congenital muscular dystrophies. Alternatively spliced transcript variants that encode different protein isoforms have been described. [provided by RefSeq, Feb 2014]
TSPAN1 (HGNC:20657): (tetraspanin 1) The protein encoded by this gene is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.923
PP5
Variant 1-46196047-G-A is Pathogenic according to our data. Variant chr1-46196047-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 558512.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-46196047-G-A is described in Lovd as [Likely_pathogenic]. Variant chr1-46196047-G-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152110Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
2
AN:
152110
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251224Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135842
GnomAD3 exomes
AF:
AC:
2
AN:
251224
Hom.:
AF XY:
AC XY:
2
AN XY:
135842
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000137 AC: 20AN: 1461726Hom.: 0 Cov.: 31 AF XY: 0.0000165 AC XY: 12AN XY: 727154
GnomAD4 exome
AF:
AC:
20
AN:
1461726
Hom.:
Cov.:
31
AF XY:
AC XY:
12
AN XY:
727154
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152110Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74300
GnomAD4 genome
AF:
AC:
2
AN:
152110
Hom.:
Cov.:
33
AF XY:
AC XY:
2
AN XY:
74300
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
3
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:9Uncertain:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2023 | POMGNT1: PM3:Strong, PM1, PM2, PP3, PS3:Supporting - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 25, 2022 | Residue is located within the carbohydrate-binding stem domain and has been shown to modulate O-mannosylation of the alpha-dystroglycan protein; disruptions of this position destabilize the POMGNT1 enzyme, leading to decreased catalytic activity (Kuwabara et al., 2016); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 34426522, 34324503, 28688748, 27493216, 30961548) - |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 18, 2024 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 08, 2021 | NM_017739.3(POMGNT1):c.385C>T(R129W) is a missense variant classified as likely pathogenic in the context of POMGNT-related disorders. R129W has been observed in cases with relevant disease (PMID: 28688748, 30961548, Kritioti_2019_(no PMID; abstract)). Functional assessments of this variant are not available in the literature. R129W has been observed in population frequency databases (gnomAD: NFE <0.001%). In summary, NM_017739.3(POMGNT1):c.385C>T(R129W) is a missense variant that has been observed more frequently in cases with the relevant disease than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Muscle eye brain disease Pathogenic:1Uncertain:1
Likely pathogenic, criteria provided, single submitter | research | Cytogenetics and Genomics Lab, Cyprus Institute Of Neurology and Genetics | Apr 10, 2020 | - - |
Uncertain significance, flagged submission | clinical testing | Natera, Inc. | Jan 31, 2020 | - - |
Muscular dystrophy-dystroglycanopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 24, 2023 | The p.Arg129Trp variant in POMGNT1 has been reported in at least five individuals with POMGNT1-associated muscular dystrophy-dystroglycanopathy (PMID: 28688748, PMID: 30961548, PMID: 34324503, ClinVar SCV002029242.2), and has been identified in 0.002% (2/113568) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs375431575). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID #558512) and has been interpreted as pathogenic by Invitae and CeGaT Center for Human Genetics Tuebingen, as likely pathogenic by Molecular Genetics (Royal Melbourne Hospital), Cytogenetics and Genomics Lab (Cyprus Institute Of Neurology and Genetics), and Myriad Women's Health, Inc., and as of uncertain significance by Counsyl, Illumina, and Natera, Inc. Of the five affected individuals, two were compound heterozygotes who carried a reported pathogenic or likely pathogenic variant in trans, which increases the likelihood that the p.Arg129Trp variant is pathogenic (PMID: 30961548, PMID: 34324503; ClinvarID: 56582, 984973). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for POMGNT1-associated muscular dystrophy-dystroglycanopathy. ACMG/AMP Criteria applied: PM3_Strong, PM2_supporting, PP3 (Richards 2015). - |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3;C3150417:Autosomal recessive limb-girdle muscular dystrophy type 2O;C3151519:Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3;C4310704:Retinitis pigmentosa 76 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 02, 2024 | - - |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3;C3150417:Autosomal recessive limb-girdle muscular dystrophy type 2O Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 06, 2023 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 129 of the POMGNT1 protein (p.Arg129Trp). This variant is present in population databases (rs375431575, gnomAD 0.003%). This missense change has been observed in individual(s) with muscular dystrophy-dystroglycanopathy or congenital muscular dystrophy (PMID: 28688748, 30961548, 34324503; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 558512). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt POMGNT1 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. - |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Dec 02, 2021 | This sequence change in POMGNT1 is predicted to replace arginine with tryptophan at codon 129, p.(Arg129Trp). The arginine residue is highly conserved (100 vertebrates, UCSC), and is a critical carbohydrate binding residue in the interleukin-like EMT inducer (ILEI) domain (PMID: 27493216). There is a large physicochemical difference between arginine and tryptophan. The highest population minor allele frequency in gnomAD v2.1 is 0.002% (2/113,568 alleles) in the European (non-Finnish) population, which is consistent with a recessive condition. This variant has been detected in at least four individuals with muscular dystrophy-dystroglycanopathy. Of those individuals, three were compound heterozygous for the variant and a pathogenic or likely pathogenic variant and two of those were confirmed in trans by parental testing (PMID: 28688748, 30961548, 34324503). Further, the variant has been reported to segregate with disease in a single family (PMID: 34324503). Multiple lines of computational evidence predict a deleterious effect for the missense substitution (5/6 algorithms). Based on the classification scheme RMH Modified ACMG Guidelines v1.4.0, this variant is classified as LIKELY PATHOGENIC. Following criteria are met: PM3_Strong, PM1, PM2_Supporting, PP1, PP3. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Benign
T;D;.
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
.;M;M
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D;D;D
REVEL
Pathogenic
Sift
Pathogenic
D;D;D
Sift4G
Pathogenic
D;D;D
Polyphen
D;D;.
Vest4
MVP
MPC
0.91
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at